// App-Quantinova.ai

9062 : ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Jean-Charles Soria

Principal Investigators

  • Steffan N. Ho

  • Marileila Varella-Garcia

  • A. John Iafrate

  • Benjamin J. Solomon

  • Alice T. Shaw

  • Fiona Helen Blackhall

  • Tony Mok

  • Yi-Long Wu

  • Ekaterina Pestova

  • Fred W. Siebert

  • Keith D. Wilner

  • Anna Polli

  • Jolanda Paolini

  • Silvana Lanzalone

  • Stephanie J. Green

  • D. Ross Camidge

Medical Centers

  • Institut Gustave-Roussy, Villejuif, France

  • Pfizer Oncology, La Jolla, CA

  • University of Colorado Cancer Center, Aurora, CO

  • Massachusetts General Hospital, Boston, MA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom

  • Chinese University of Hong Kong, Shatin, China

  • Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China

  • Abbott Laboratories, Des Plaines, IL

  • Pfizer Inc, Milan, Italy

  • Pfizer Oncology, Groton, CT

  • University of Colorado Cancer Center, Aurora, CO

Locations

  • China

  • Italy

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

Drug/Treatment

  • Crizotinib

Outcome

  • N/A

Study Design

  • Single Arm

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved